Skip to main content

Danish Partners Embark on $6.8M Personalized Cancer Diagnostics Project

NEW YORK (GenomeWeb News) – Partners in Denmark have joined to embark on a €5.2 million ($6.8 million) personalized cancer diagnostic project.

The project aims to develop a platform for precision medicine using gene expression analysis so that individual cancer patients can receive treatments that have been tailored specifically for them.

The members of the project are Vejle Hospital, the Technical University of Denmark, Exiqon, and Intomics. The five-year project will focus on colorectal cancer, and the Danish National Advanced Technology Foundation has provided €3.0 million toward it.

The hospital has conducted research into colorectal cancer, it said, and will contribute research with "well-defined patient groups." Exiqon will provide its expertise in and technology for measuring genetic biomarkers, while Intomics and the university provides their bioinformatics expertise in handling large amounts of complex genetic data.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.